Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Sergey Yurasov_2023
VIEWPOINTS

Sergey Yurasov Shares Insights on Initial Dose Escalation Data of BDTX-1535 for the Treatment of Non-Small Cell Lung Cancer Patients

Shots:  During the initial part of conversation, Sergey discussed details about the BDTX-1535 and the trial design of the P-I study where 1535 is being investigated in NSCLC and GBM patients  He then discussed the insights drawn from the first 51 patients recruited in the dose escalation part of the P-I study In the final…
October 3, 2023

Read more

Viewpoint_Dr.Jing_Watnick_&_Dr. Lou_Vaickus_2021
VIEWPOINTS

PharmaShots Interview: Vigeo Therapeutics’ Dr. Lou Vaickus and Dr. Jing Watnick Share Insights on VT1021 Data Presented at SITC 2020

In a recent interview with PharmaShots, Dr. Jing Watnick, Co-Founder and Chief Executive Officer, and Dr. Lou Vaickus, Interim Chief Medical Officer at Vigeo shared their views on the data findings presented at the SITC 2020 Annual Meeting that demonstrated VT1021 as a single-agent has a favorable safety profile and shows early signals of clinical activity across a wide variety of…
January 15, 2021

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]